

**PCT**  
**INTERNATIONAL SEARCH REPORT**  
(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference <b>12551050</b>	<b>FOR FURTHER ACTION</b> <div style="text-align: right; font-size: small;">see Form PCT/ISA/220 as well as, where applicable, item 5 below.</div>	
International application No. <b>PCT/AU2004/001840</b>	International filing date ( <i>day/month/year</i> ) <b>23 December 2004</b>	(Earliest) Priority Date ( <i>day/month/year</i> ) <b>24 December 2003</b>
Applicant <b>THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH et al</b>		

This international search report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This international search report consists of a total of **4** sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

**I. Basis of the report**

- a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ The international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

- b. ☐ With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, see Box No. I.

2. ☐ Certain claims were found unsearchable (See Box No. II).

3. ☐ Unity of invention is lacking (See Box No. III).

4. With regard to the **title**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established by this Authority to read as follows:

5. With regard to the **abstract**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box No. IV. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. With regard to the **drawings**,

- a. the figure of the drawings to be published with the abstract is Figure No. **5**

☐ as suggested by the applicant.

☒ as selected by this Authority, because the applicant failed to suggest a figure.

☐ as selected by this Authority, because this figure better characterizes the invention.

- b. ☐ none of the figures is to be published with the abstract.

**A. CLASSIFICATION OF SUBJECT MATTER**Int. Cl. <sup>7</sup>: A61K 38/45, 38/19, A61P 35/00, 37/02

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

**SEE THE ELECTRONIC DATABASES SEARCHED BELOW**

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

DWPI: Autoimmune, Cancer, Diabetes, Neoplasm, Tumor, Tumour, Malignant, Beta cell, Pancreatic, Dendritic cell, FLT-3 Ligand (and the like).

MEDLINE, CA: As above.

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	MALISZEWSKI C Dendritic cells in models of tumor immunity. Role of Flt3 ligand. Pathol. Biol. 2001, Vol. 49, pages 481-483. Entire document.	1-27
X	MOREL P ET. AL. Immunobiology of DC in NOD mice. J. Leuk. Biol. 1999, Vol. 66, pages 276-280. column 3 paragraph 3 column 3 paragraph 6 column 6 paragraph 3 figure 4	1-12
X	US 2003/0113341 A1 (LYNCH ET. AL.) 19 June 2003. claims 1, 4 and 9 examples 3-6 [0020] [0008] [0012] [0015]	13-23



Further documents are listed in the continuation of Box C



See patent family annex

\* Special categories of cited documents:

"A"	document defining the general state of the art which is not considered to be of particular relevance	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E"	earlier application or patent but published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another: citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O"	document referring to an oral disclosure, use, exhibition or other means	"&"	document member of the same patent family
"P"	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

21 February 2005

Date of mailing of the international search report

16 MAR 2005

Name and mailing address of the ISA/AU

AUSTRALIAN PATENT OFFICE  
PO BOX 200, WODEN ACT 2606, AUSTRALIA  
E-mail address: pct@ipaustralia.gov.au  
Facsimile No. (02) 6285 3929

Authorized officer

**TAMARA NIZNIK**

Telephone No : (02) 6283 2422

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	MCNEEL D ET. AL. Pilot Study of an HLA-A2 Peptide Vaccine Using Flt3 Ligand as a Systemic Vaccine Adjuvant. J. Clin. Immunol. 2003, Vol. 23, No. 1, pages 62-72. figure 2 column 3 paragraph 1 – column 5 paragraph 1 column 8 paragraph 3 – column 9 paragraph 1 column 14 paragraph 2 – column 16 paragraph 1	13-23
X	DONG J ET. AL. Flt-3 Ligand A Potent Dendritic Cell Stimulator and Novel Antitumor Agent. Cancer Biology & Therapy. 2002, Vol. 1, No. 5, pages 486-488. column 1 paragraph 3 column 2 paragraph 2 column 3 paragraphs 2-4 column 4 paragraph 4	13-23
X	RINI B I ET. AL. Flt-3 Ligand and Sequential FL/Interleukin-2 in Patients With Metastatic Renal Carcinoma: Clinical and Biologic Activity. Journal of Immunotherapy. 2002, Vol. 25, No. 3, pages 269-277. figure 4 column 2 paragraph 2 column 3 paragraph 2 column 4 paragraph 4 - column 5 paragraph 1 column 16 paragraph 4 - column 17 paragraph 2	13-23
A	WO 2002/100317 A2 (THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA) 19 December 2002	
A	WO 2002/067760 A2 (BAYLOR RESEARCH INSTITUTE) 6 September 2002	

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report				Patent Family Member			
US	2003113341	AU	73922/96	BR	9610802	CA	2232865
		CN	1229359	CZ	9800977	EE	9800105
		EP	0871487	LV	12085	NO	981374
		NZ	321039	PL	325964	SI	9620116
		SK	40898	US	2002034517	US	2003165531
		US	2004037845	WO	9712633		
WO	02100317						
WO	02067760	CA	2433806	EP	1351707	US	2002160974
		US	2004067232				
Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001.							
END OF ANNEX							